Lanreotide depot/autogel before, during, and after peptide receptor radionuclide therapy (PRRT) in advanced neuroendocrine tumors (NETs): Data from the PRELUDE study

Vikas Prasad,Raj Srirajaskanthan,Christos Toumpanakis,Chiara Grana,Sergio Baldari,Tahir Shah,Angela Lamarca,F. Courbon,K. Scheidhauer,Eric Baudin,Xuan-Mai Truong Thanh,Aude Houchard,Lisa Bodei

Lanreotide depot/autogel before, during, and after peptide receptor radionuclide therapy (PRRT) in advanced neuroendocrine tumors (NETs): Data from the PRELUDE study

2018

Vikas Prasad
Raj Srirajaskanthan
Christos Toumpanakis
Chiara Grana
Sergio Baldari
Tahir Shah
Angela Lamarca
F. Courbon
K. Scheidhauer
Eric Baudin
Xuan-Mai Truong Thanh
Aude Houchard
Lisa Bodei

e16167Background: PRRT, licensed for gastroenteropancreatic (GEP) NETs, has been used with somatostatin analogs such as lanreotide depot (LAN). PRELUDE is the first retrospective study to describe ...

Keywords:

Lanreotide
Cancer research
Neuroendocrine tumors
Peptide
Receptor
Medicine
Depot
peptide receptor
radionuclide therapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations